Literature DB >> 7261254

Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse.

P B Johansen.   

Abstract

The pharmacokinetics of doxorubicin in nude mice have been investigated following intravenous and intraperitoneal administration of single doses of 12 mg/kg. The areas under the concentration curves of doxorubicin in kidney, heart, and striated muscle following intraperitoneal administration were approximately half the areas following intravenous injection, whereas plasma and liver showed nearly identical concentrations after a distribution phase of 2 h. Only minor differences in pharmacokinetics were found between nude and normal mice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7261254     DOI: 10.1007/BF00434396

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.

Authors:  R F Ozols; G Y Locker; J H Doroshow; K R Grotzinger; C E Myers; R C Young
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

2.  Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity.

Authors:  E Arena; N D'Alessandro; L Dusonchet; N Gebbia; F Gerbasi; M Palazzoadriano; A Raineri; L Rausa; E Tubaro
Journal:  Arzneimittelforschung       Date:  1971-08

3.  On the reported lack of effectiveness of daunomycin (NSC-82151) and adriamycin (NSC-123127) on solid tumors.

Authors:  L Lenaz; A Di Marco
Journal:  Cancer Chemother Rep       Date:  1972-08

4.  Distribution and metabolism of adriamycin in mice. Comparison with daunomycin.

Authors:  G Di Fronzo; R A Gambetta; L Lenaz
Journal:  Rev Eur Etud Clin Biol       Date:  1971 Jun-Jul

5.  DNA--anthracycline complexes. II. Comparative study of the acute lesions induced in mice after intravenous administration of free and DNA bound adriamycin.

Authors:  D Deprez-de Campeneere; R Jaenke; A Trouet; H Baudon; P Maldague
Journal:  Eur J Cancer       Date:  1980-08       Impact factor: 9.162

6.  The interaction between adriamycin and radiation in a solid murine tumor.

Authors:  D W Siemann; R M Sutherland
Journal:  Radiat Res       Date:  1980-08       Impact factor: 2.841

7.  Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.

Authors:  M A Pacciarini; B Barbieri; T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Cancer Treat Rep       Date:  1978-05

8.  Antineoplastic activity and pharmacokinetics of adriamycin and daunomycin in tumor bearing mice.

Authors:  A Martini; N G Donelli; A Mantovani; M A Pacciarini; E F Fogar-Ottaviano; L Morasca; S Garattini; F S Spreafico
Journal:  Oncology       Date:  1977       Impact factor: 2.935

9.  Alterations in adriamycin efficacy by phenobarbital.

Authors:  S D Reich; N R Bachur
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

10.  Biodistribution of intravenously injected [14C] doxorubicin and [14C] daunorubicin in mice: concise communication.

Authors:  K Harrison; N H Wagner
Journal:  J Nucl Med       Date:  1978-01       Impact factor: 10.057

View more
  29 in total

1.  TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Leonardo F Ferreira; Michael B Reid
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

Review 2.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

3.  Single Protein Encapsulated Doxorubicin as an Efficacious Anticancer Therapeutic.

Authors:  Changjun Yu; Faqing Huang; Warren A Chow; Galen Cook-Wiens; Xiaojiang Cui
Journal:  Adv Ther (Weinh)       Date:  2020-10-12

4.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

5.  A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships.

Authors:  Yadir A Guerrero; Diti Desai; Connor Sullivan; Erick Kindt; Mary E Spilker; Tristan S Maurer; Deepak E Solomon; Derek W Bartlett
Journal:  AAPS J       Date:  2020-03-02       Impact factor: 4.009

6.  The biological characteristics and chemosensitivity of anaplastic thyroid carcinoma transplanted into nude mice.

Authors:  A Yoshida; M Fukazawa; Y Aiyoshi; S Soeda; K Ito
Journal:  Jpn J Surg       Date:  1990-11

7.  A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.

Authors:  Hua He; Can Liu; Yun Wu; Xinyuan Zhang; Jianghong Fan; Yanguang Cao
Journal:  Pharm Res       Date:  2018-07-09       Impact factor: 4.200

8.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

9.  Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine.

Authors:  P B Johansen; S E Jensen; S N Rasmussen; M Dalmark
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.

Authors:  Stuart Ibsen; Eran Zahavy; Wolf Wrasidlo; Tomoko Hayashi; John Norton; Yongxuan Su; Stephen Adams; Sadik Esener
Journal:  Photochem Photobiol       Date:  2013-03-06       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.